Press Releases

This section of Viatris.com contains information that may not be suitable for use in all countries due to varied regulatory requirements, data protection requirements and practices or medical practices, and distinctions among product approval and commercial availability. The information contained in each news release or statement posted on this page is presented as of the date it was issued. The company undertakes no obligation to update the information for changes or subsequent events after the date it was originally issued.

Month Year

Feb 28, 2022

Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted EBITDA(1), the First in a Series of Expected Initiatives Anticipated to Unlock up to an Additional $6 Billion in Pre-tax Proceeds by the End of 2023; Board of Directors Authorizes a Share Repurchase Program of up to $1 Billion, Maintaining Company Commitment to Return Capital to Shareholders
Feb 4, 2022

Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
Feb 3, 2022

Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease

Approval Reinforces Viatris' Steadfast Commitment to Breaking Down Barriers and Expanding Access to Complex Generic Products
Jan 18, 2022

Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (insulin glargine injection), 100 units/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch
Jan 6, 2022

Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend
Dec 29, 2021

Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations

Decisions reaffirm Viatris' ability to provide patient access to interchangeable Semglee®
Dec 17, 2021

Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results
Dec 6, 2021

Viatris Named by Newsweek as One of America's Most Responsible Companies
Dec 1, 2021

Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent
Nov 18, 2021

Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

Localized information for Malaysia

Localized information for Malaysia

Leaving this page

Press Releases

Localized information for Malaysia

Localized information for Malaysia

Leaving this page

Leaving the Viatris site

Press Releases